Two-stage adaptive design for clinical trials with survival data.
In long-term clinical trials we often need to monitor the patients' enrollment, compliance, and treatment effect during the study. In this paper we take the conditional power approach and consider a two-stage design based on the ideas of Li et al. (2002) for trials with survival endpoints. We make projections and decisions regarding the future course of the trial from the interim data. The decision includes possible early termination of the trial for convincing evidence of futility or efficacy, and projection includes how many additional patients are needed to enroll and how long the enrollment and follow-up may be when continuing the trial. The flexibility of the adaptive design is demonstrated by an example, the Coumadin Aspirin Reinfarction Study.
Li
Gang
G
Clinical Biostatistics, Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey, USA. ligang8844@yahoo.com
Shih
Weichung J
WJ
Wang
Yining
Y
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D009203:Myocardial Infarction / Q000517:prevention & control; D010349:Patient Compliance; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D055502:Secondary Prevention; D016019:Survival Analysis; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin